Physician profile
Eric R Batres
NPI 1174638373
$13,146.91
in general payments reported to CMS, 2019-2025
50 companies · $1,657 in 2025
The $1,657 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,578 · 2020: $2,376 · 2021: $2,073 · 2022: $1,823 · 2023: $1,617 · 2024: $2,021 · 2025: $1,657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,205 · Education: $90.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,204.82 |
| Education | $90.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,260.29 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Janssen Pharmaceuticals, INC | $1,205.01 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $989.59 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $948.41 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $932.72 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $916.42 | 2019-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $837.93 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $760.96 | 2019-2025 | |
| Amgen INC. | $607.64 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Merck Sharp & Dohme LLC | $506.73 | 2019-2024 | Verquvo, Gardasil 9, Vaxelis |
| Bayer Healthcare Pharmaceuticals INC. | $457.89 | 2021-2025 | |
| Amarin Pharma, INC. | $419.20 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $325.35 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $303.22 | 2024-2025 | Gemtesa |
| Astellas Pharma US INC | $213.51 | 2021-2025 | Veozah, Myrbetriq |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $202.00 | 2020-2023 | Linzess |
| E.R. Squibb & Sons, L.L.C. | $201.84 | 2020-2025 | Eliquis |
| Mannkind Corporation | $183.91 | 2020-2025 | Afrezza |
| Lundbeck LLC | $173.60 | 2023-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $166.43 | 2020-2022 | |
| Dexcom, INC. | $156.55 | 2023-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $123.22 | 2023-2025 | Rexulti |
| Smith+Nephew, INC. | $104.50 | 2020-2025 | Collagenase Santyl, Regranex |
| Radius Health, INC. | $98.32 | 2020 | |
| Sanofi Pasteur INC. | $86.77 | 2020-2023 | |
| Medtronic, INC. | $78.13 | 2021-2022 | |
| Abbott Laboratories | $72.96 | 2019-2023 | Proclaim |
| Eisai INC. | $69.32 | 2025 | |
| Horizon Therapeutics Plc | $66.39 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $59.66 | 2021-2025 | Gvoke Hypopen |
| Allergan, INC. | $57.10 | 2019 | |
| Shield Therapeutics INC | $49.89 | 2023 | Accrufer |
| Hologic Sales and Service, LLC | $48.87 | 2023 | Aptima, Thinprep 2000 Processor |
| Ultragenyx Pharmaceutical INC. | $48.79 | 2020-2021 | |
| Phadia US INC. | $47.37 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $47.36 | 2024-2025 | Voquezna |
| Corcept Therapeutics | $43.07 | 2020-2025 | Korlym |
| Esperion Therapeutics, INC. | $41.94 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $33.12 | 2025 | Rexulti |
| Averitas Pharma INC. | $31.58 | 2024 | Qutenza |
| Vistapharm, INC. | $29.43 | 2021 | |
| Lifescan, INC. | $20.71 | 2022 | |
| Exact Sciences Corporation | $19.41 | 2025 | Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $18.51 | 2020 | |
| Theracosbio, LLC | $18.18 | 2024 | Brenzavvy |
| Seqirus USA INC | $17.02 | 2025 | Fluad, Flucelvax |
| Microtransponder, INC. | $16.38 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.03 | 2025 | Trintellix |
| Arbor Pharmaceuticals, INC. | $11.97 | 2020 | |
| Janssen Biotech, INC. | $2.71 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Batres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.